Duvakitug, an investigational monoclonal antibody targeting interleukin-23, has demonstrated efficacy as an induction therapy for patients with inflammatory bowel disease (IBD), according to new research reported in MedPage Today. The findings add to the evolving landscape of advanced biologics for Crohn’s disease and ulcerative colitis.
Background Context
Interleukin-23 (IL-23) is a pro-inflammatory cytokine that plays a central role in the pathogenesis of IBD. It promotes the differentiation and survival of T helper 17 cells, which contribute to chronic intestinal inflammation. Several IL-23 inhibitors have already entered clinical use in IBD, including risankizumab and mirikizumab, both of which target the p19 subunit of IL-23. Duvakitug represents another agent in this therapeutic class, designed to block IL-23 signalling and reduce inflammation in the gut. The drug is currently under investigation for both Crohn’s disease and ulcerative colitis.
Key Findings
Researchers investigating duvakitug reported that the drug could serve as an effective induction therapy for patients with IBD. The study focused on the agent’s ability to induce clinical response and remission during the initial treatment phase, a critical period for establishing disease control in newly diagnosed or flaring patients. Whilst the MedPage Today report did not provide granular efficacy data or patient numbers, it confirmed that the investigational treatment showed promise in early evaluation. Duvakitug is administered as a monoclonal antibody therapy, targeting the same inflammatory pathway as other IL-23 inhibitors currently in clinical use. The findings contribute to a broader pattern of increasing reliance on advanced therapies, including biologics and small molecules, in the management of moderate to severe IBD.
Clinical Relevance
The potential addition of duvakitug to the IL-23 inhibitor class offers gastroenterologists another option in an increasingly crowded therapeutic landscape. For patients with IBD who have failed conventional therapies or other biologics, additional agents targeting different epitopes or offering distinct pharmacokinetic profiles may improve the likelihood of achieving remission. The focus on induction efficacy is particularly relevant, as rapid control of inflammation can reduce the risk of complications, hospitalisations, and the need for surgery. Clinicians will await full publication of trial data, including safety profiles, durability of response, and head-to-head comparisons with existing IL-23 inhibitors, before incorporating duvakitug into treatment algorithms.
Reference
MedPage Today. Novel Drug Shows Promise in Crohn’s, Ulcerative Colitis. Published April 2025. Available at: https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/122272
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.